Table 5.
Significant gene ontology (GO) enrichment results (by GAUSS) after correction of multiple testing (FDR < 0.05)
| GeneSet | Pvalue | Phenotype | FDR adjust Pa |
|---|---|---|---|
| GO_SPHINGOLIPID_MEDIATED_SIGNALING_PATHWAY | 6.88E-09 | CDICT_Total | 4.07E-05 |
| GO_GLYCEROPHOSPHOLIPID_CATABOLIC_PROCESS | 6.40E-08 | PureC_Total | 3.78E-04 |
| GO_PROTON_TRANSPORTING_V_TYPE_ATPASE_COMPLEX | 1.20E-07 | CWR_Norm | 7.13E-04 |
| GO_ALCOHOL_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 2.38E-07 | RC_MC | 1.41E-03 |
| GO_DIVALENT_INORGANIC_ANION_HOMEOSTASIS | 5.74E-07 | PureC_Total | 1.70E-03 |
| GO_CELLULAR_ANION_HOMEOSTASIS | 2.25E-06 | PureC_Total | 4.44E-03 |
| GO_BIOACTIVE_LIPID_RECEPTOR_ACTIVITY | 2.13E-06 | CDICT_Total | 6.29E-03 |
| GO_ATP_HYDROLYSIS_COUPLED_TRANSMEMBRANE_TRANSPORT | 2.22E-06 | EWR_Total | 1.31E-02 |
| GO_LYMPHANGIOGENESIS | 7.35E-06 | CDICT_Total | 1.45E-02 |
| GO_ORGANIC_HYDROXY_COMPOUND_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 4.90E-06 | RC_MC | 1.45E-02 |
| GO_POSITIVE_REGULATION_OF_VASODILATION | 2.00E-05 | PureC_Total | 1.48E-02 |
| GO_POSITIVE_REGULATION_OF_B_CELL_DIFFERENTIATION | 2.00E-05 | PureC_Total | 1.48E-02 |
| GO_POSITIVE_REGULATION_OF_BLOOD_CIRCULATION | 2.00E-05 | PureC_Total | 1.48E-02 |
| GO_NEURON_PROJECTION_GUIDANCE | 2.00E-05 | PureC_Total | 1.48E-02 |
| GO_POLYSACCHARIDE_BINDING | 2.00E-05 | PureC_Total | 1.48E-02 |
| GO_MONOVALENT_INORGANIC_ANION_HOMEOSTASIS | 3.00E-05 | PureC_Total | 1.97E-02 |
| GO_REGULATION_OF_MITOCHONDRIAL_FISSION | 1.53E-05 | CDICT_Total | 2.27E-02 |
| GO_RESPONSE_TO_NERVE_GROWTH_FACTOR | 1.08E-05 | EWR_Total | 2.43E-02 |
| GO_PROTON_TRANSPORTING_TWO_SECTOR_ATPASE_COMPLEX_CATALYTIC_DOMAIN | 1.64E-05 | EWR_Total | 2.43E-02 |
| GO_PROTON_TRANSPORTING_V_TYPE_ATPASE_COMPLEX | 1.35E-05 | EWR_Total | 2.43E-02 |
| GO_LIGAND_GATED_CHANNEL_ACTIVITY | 4.14E-06 | EDRAN_Mean | 2.45E-02 |
| GO_HYDROGEN_TRANSPORT | 3.00E-05 | EWR_Total | 2.96E-02 |
| GO_VACUOLAR_PROTON_TRANSPORTING_V_TYPE_ATPASE_COMPLEX | 3.00E-05 | EWR_Total | 2.96E-02 |
| GO_RNA_CAP_BINDING_COMPLEX | 5.34E-06 | CDC_Total | 3.16E-02 |
| GO_POSITIVE_REGULATION_OF_MITOCHONDRIAL_FISSION | 3.00E-05 | CDICT_Total | 3.29E-02 |
| GO_DIOL_METABOLIC_PROCESS | 4.00E-05 | CDICT_Total | 3.29E-02 |
| GO_LYMPH_VESSEL_MORPHOGENESIS | 5.00E-05 | CDICT_Total | 3.29E-02 |
| GO_LYMPH_VESSEL_DEVELOPMENT | 5.00E-05 | CDICT_Total | 3.29E-02 |
| GO_VENOUS_BLOOD_VESSEL_DEVELOPMENT | 4.00E-05 | CDICT_Total | 3.29E-02 |
| GO_G_PROTEIN_COUPLED_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY | 5.61E-06 | CVK_Total | 3.32E-02 |
| GO_ORGANIC_HYDROXY_COMPOUND_TRANSPORT | 5.00E-05 | RC_MC | 3.70E-02 |
| GO_NERVE_DEVELOPMENT | 5.00E-05 | RC_MC | 3.70E-02 |
| GO_BLOOD_VESSEL_REMODELING | 2.09E-05 | RC_MC | 3.70E-02 |
| GO_KINETOCHORE | 5.00E-05 | RC_MC | 3.70E-02 |
| GO_CONDENSED_CHROMOSOME_CENTROMERIC_REGION | 5.00E-05 | RC_MC | 3.70E-02 |
| GO_CONDENSED_NUCLEAR_CHROMOSOME_CENTROMERIC_REGION | 5.00E-05 | RC_MC | 3.70E-02 |
| GO_DETECTION_OF_LIGHT_STIMULUS | 6.00E-05 | RC_MC | 3.94E-02 |
| GO_STEROID_BINDING | 7.00E-05 | PureC_Total | 4.14E-02 |
| GO_G_PROTEIN_COUPLED_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY | 7.58E-06 | CVD_Total | 4.48E-02 |
| GO_WNT_SIGNALING_PATHWAY_CALCIUM_MODULATING_PATHWAY | 2.31E-05 | CCR_Total | 4.56E-02 |
| GO_LOCOMOTORY_EXPLORATION_BEHAVIOR | 2.00E-05 | CCR_Total | 4.56E-02 |
| GO_RNA_CAP_BINDING_COMPLEX | 2.00E-05 | CCR_Total | 4.56E-02 |
| GO_LIPASE_ACTIVATOR_ACTIVITY | 8.00E-05 | CDICT_Total | 4.73E-02 |
| GO_DRUG_TRANSPORTER_ACTIVITY | 8.07E-06 | CVA_Total | 4.78E-02 |
| GO_POSITIVE_REGULATION_OF_B_CELL_ACTIVATION | 9.00E-05 | PureC_Total | 4.84E-02 |
Please refer to Table 10 for abbreviations of the phenotypes. Full descriptions of each gene-set can be found by looking up the pathway names at https://www.gsea-msigdb.org/gsea/msigdb/.
aFDR-adjust P: Calculated by the R.program p.adjust using Benjamini-Hochberg procedure (BH).